Bank of England minutes released this morning revealed the continuing dovish policy being adopted by central banks, which has done so much to bolster confidence across the stock markets, and has encouraged sterling to resume its downward trend versus the dollar.
A generally bleak picture was painted across both the UK and international markets, with few if any signs of inflationary pressures domestically. Read more [...]
Facebook Inc (NASDAQ:FB) is suing several law firms that represented a man who claimed he owned half of the social network and was entitled to billions of dollars from the company and its CEO Mark Zuckerberg. Facebook Inc (NASDAQ:FB)’s stock on 20 October traded at beginning with a price of $75.60 and when day-trade ended the stock finally moved up 1.32% to end at $76.95. Facebook Inc (NASDAQ:FB)’s Read more [...]
Gilead Sciences Inc. (NASDAQ:GILD) on Oct. 10 announced that the U.S. Food and Drug Administration (FDA) has approved Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, approved under Read more [...]
NewLink Genetics Corporation (NASDAQ:NLNK) announced that it made a deal with Roche Holding AG in developing NewLink’s cancer immunotherapy dug receiving up to $1 billion in milestone payment. NewLink is the same company that has developed the Ebola vaccine that will be soon tested in Geneva. NewLink Genetics Corporation (NASDAQ:NLNK)’s stock on 20 October traded at beginning with a price of $35.73 Read more [...]
Neuralstem, Inc. (NYSEMKT:CUR) on Oct. 9 announced that the first patient was treated last week in the Phase I trial testing NSI-566 human neural stem cells in the treatment of chronic spinal cord injury (cSCI) at the UC San Diego School of Medicine. The patient has been discharged from the hospital. The NSI-566/cSCI Phase I trial will treat four patients who have thoracic spinal cord injuries (T2-T12) Read more [...]
SunEdison, Inc., (NYSE:SUNE) a leading solar developer and technology provider, announced a joint venture agreement with JIC Capital, to facilitate nonrecourse financing and develop, construct and own up to 1 GW of utility-scale solar photovoltaic (PV) projects in China over the next 3 years. SunEdison, Inc. (NYSE:SUNE)’s stock on 20 October traded at beginning with a price of $16.58 and when day-trade Read more [...]